Our Services
Medical Information
Helpful Resources
Published on: 3/12/2026
If Humira is no longer controlling your Crohn’s, first confirm true inflammation and check Humira drug and antibody levels, since adjusting the dose or adding an immunomodulator may restore benefit.
If failure is confirmed, many do well by switching to Stelara or Skyrizi, with Entyvio, Rinvoq, or sometimes another anti-TNF as alternatives, but the right choice depends on why Humira failed, disease features, and safety considerations; see below for key details that can change your next steps.
If you're living with Crohn's disease and Humira (adalimumab) isn't working anymore — or never worked well in the first place — you're not alone. Many people eventually need to switch therapies. It's frustrating, especially if you had high hopes for relief.
The good news? You still have options. And in many cases, switching treatments can bring symptoms back under control.
Let's walk through why Humira may fail, what it means for your health, and the best medication for Crohn's when Humira fails, based on current medical evidence and treatment guidelines.
Humira is a biologic medication that blocks tumor necrosis factor (TNF), a key driver of inflammation in Crohn's disease. It's often one of the first advanced therapies doctors prescribe.
But it doesn't work for everyone — and even if it does at first, it may lose effectiveness over time.
There are three main reasons:
This means Humira never worked well from the start. About 10–30% of patients fall into this category. Your body simply didn't respond to TNF-blocking therapy.
Humira worked initially but stopped working later. This happens in up to 40% of patients over time.
Common causes include:
Not all flares are caused by active Crohn's inflammation. Symptoms can also be due to:
This is why doctors often check:
Before switching medications, your doctor should confirm whether Humira truly failed or whether adjustments can be made.
Sometimes Humira hasn't actually failed — it just needs adjustment.
Your doctor may:
If drug levels are low without antibodies, increasing the dose may restore effectiveness.
If antibodies are present, switching medications is often necessary.
If Humira truly isn't working, the next step depends on why it failed and your disease pattern.
Here are the main evidence-based options.
If Humira stopped working due to antibodies — but you initially responded well — switching to another anti-TNF like:
can still work.
However, if you never responded to Humira at all (primary non-response), switching within the same class is less likely to help.
Stelara targets different inflammatory pathways (IL-12 and IL-23), not TNF.
Why doctors like it after Humira failure:
Clinical trials show many patients achieve remission after switching to Stelara when anti-TNFs stop working.
For many patients, this becomes the best medication for Crohn's when Humira fails, especially after antibody development or primary non-response.
Skyrizi targets IL-23 specifically and is one of the newer Crohn's treatments.
Benefits:
This is emerging as a leading option for patients who don't respond to TNF blockers.
Entyvio works differently — it blocks gut-specific immune activity instead of suppressing the entire immune system.
Pros:
Cons:
For patients concerned about infection risk, this can be a strong alternative.
These are oral medications that work inside immune cells to block inflammation signals.
Benefits:
Risks:
These are typically reserved for moderate-to-severe cases after other biologics fail.
There is no single "right" answer for everyone. The best medication for Crohn's when Humira fails depends on:
This decision should always be individualized.
Sometimes persistent symptoms are not active Crohn's inflammation.
Your doctor may check:
If inflammation is low, your symptoms might be due to IBS overlap, scar tissue, or another inflammatory bowel condition. Since Crohn's and Ulcerative Colitis can sometimes present with overlapping symptoms, using a free online assessment tool can help you identify whether your specific symptom pattern may warrant additional testing or a second opinion about your diagnosis.
If medications repeatedly fail or if complications develop, surgery may be recommended.
Reasons include:
Surgery is not a failure — for some patients, it significantly improves quality of life.
If Humira isn't working:
It's discouraging when a medication fails. But modern Crohn's treatment has evolved significantly in the past decade. There are now multiple targeted therapies with different mechanisms of action.
Many patients achieve remission after switching.
What matters most is:
Seek immediate medical attention if you experience:
These can be serious or life-threatening and require urgent evaluation.
If Humira failed, it does not mean you are out of options.
Today's treatment landscape offers multiple effective alternatives. In many cases, switching to a different class of medication — such as Stelara or Skyrizi — becomes the best medication for Crohn's when Humira fails.
The key is proper evaluation and a thoughtful treatment plan.
Always speak to a doctor or gastroenterologist about persistent flares, medication changes, or any serious or worsening symptoms. Crohn's disease is manageable — but only when treated proactively and carefully.
(References)
* Billiet T, Papamichael K, de Vries A, Vande Casteele N, Van Assche G, Ferrante M, Vermeire S, Gils A. Immunogenicity of Adalimumab in Crohn's Disease. Expert Rev Gastroenterol Hepatol. 2016;10(9):983-93. doi: 10.1080/17474124.2016.1197824. PMID: 27367807.
* Papamichael K, Vande Casteele N, Ferrante M, Gils A, Van Assche G, Vermeire S. Therapeutic drug monitoring of adalimumab in inflammatory bowel disease: current insights and future directions. Therap Adv Gastroenterol. 2018 Jan;11:1756283X17743952. doi: 10.1177/1756283X17743952. PMID: 29339943; PMCID: PMC5759160.
* Sands BE, Sandborn WJ. Crohn's Disease: What to Do When Anti-TNF Therapy Fails. Gastroenterology. 2018 Jan;154(1):16-29. doi: 10.1053/j.gastro.2017.10.024. PMID: 29175373.
* Papamichael K, Cheifetz AS, Jairath V, Feagan BG. Optimizing treatment after failure of tumor necrosis factor antagonists in inflammatory bowel disease. Gastroenterology. 2017 Aug;153(2):392-404. doi: 10.1053/j.gastro.2017.06.002. PMID: 28629088.
* Ko M, Papamichael K, Nachman F, Ben-Horin S. Current and future therapeutic landscape in inflammatory bowel disease: Moving toward personalized medicine. World J Gastroenterol. 2019 Jul 28;25(28):3737-3759. doi: 10.3748/wjg.v25.i28.3737. PMID: 31409949; PMCID: PMC6684650.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.